Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Paradigm Biocapital Advisors LP

Q1 2024 · 13F-HR

Paradigm Biocapital Advisors LPholdings as filed

Filed 2024-05-15 · accession 0001855655-24-000005

$2.84B
Reported value
34
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
670703107NUVLNUVALENT INC$313.7M11.0%4,177,830CommonSOLE
03940C100ACLXGBXARCELLX INC$265.5M9.35%3,818,095CommonSOLE
04016X101ARGXARGENX SE$217.4M7.65%552,120CommonSOLE
254604101IRONDISC MEDICINE INC$148.8M5.24%2,389,902CommonSOLE
22663K107CRNXCRINETICS PHARMACEUTICALS IN$146.3M5.15%3,124,749CommonSOLE
803607100SRPTSAREPTA THERAPEUTICS INC$139.6M4.91%1,078,346CommonSOLE
45258D105IMCRIMMUNOCORE HLDGS PLC$116.2M4.09%1,787,176CommonSOLE
52490G102LEGNLEGEND BIOTECH CORP$111.2M3.91%1,982,006CommonSOLE
04335A105ARVNARVINAS INC$107.9M3.80%2,614,935CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$107.0M3.77%2,484,874CommonSOLE
87650L103TARSTARSUS PHARMACEUTICALS INC$104.1M3.66%2,863,406CommonSOLE
15678U128CERE1EURCEREVEL THERAPEUTICS HLDNG I$98.5M3.47%2,330,508CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$93.9M3.31%2,914,975CommonSOLE
68062P106OLMAOLEMA PHARMACEUTICALS INC$89.5M3.15%7,903,600CommonSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$88.1M3.10%5,031,420CommonSOLE
92243G108PCVXVAXCYTE INC$84.7M2.98%1,239,995CommonSOLE
02083G100NVLSEURALPINE IMMUNE SCIENCES INC$84.1M2.96%2,121,163CommonSOLE
088786108BCYCBICYCLE THERAPEUTICS PLC$80.8M2.85%3,246,759CommonSOLE
04351P101ASNDUSDASCENDIS PHARMA A/S$76.8M2.70%507,952CommonSOLE
50127T109KURAKURA ONCOLOGY INC$66.9M2.35%3,135,387CommonSOLE
28036F105EWTXEDGEWISE THERAPEUTICS INC$44.6M1.57%2,446,373CommonSOLE
05280R100AUTLAUTOLUS THERAPEUTICS PLC$41.0M1.44%6,425,803CommonSOLE
984241109YMABUSDY-MABS THERAPEUTICS INC$36.3M1.28%2,233,610CommonSOLE
N44445109IMTXIMMATICS N.V$29.6M1.04%2,818,908CommonSOLE
45258J102IMVTIMMUNOVANT INC$25.8M0.91%799,054CommonSOLE
230031106CGEMCULLINAN ONCOLOGY INC$23.0M0.81%1,348,015CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$21.9M0.77%330,000CommonSOLE
20451W101CMPSCOMPASS PATHWAYS PLC$19.9M0.70%2,390,988CommonSOLE
929033108VOR BIOPHARMA INC$15.3M0.54%6,457,293CommonSOLE
98943L107ZNTLZENTALIS PHARMACEUTICALS INC$14.9M0.52%944,917CommonSOLE
00847X104AGIOAGIOS PHARMACEUTICALS INC$11.7M0.41%400,000CommonSOLE
142038108CRBUCARIBOU BIOSCIENCES INC$11.2M0.39%2,172,620CommonSOLE
14179K101CRGXCARGO THERAPEUTICS INC$3.3M0.12%147,959CommonSOLE
501976104KYTXKYVERNA THERAPEUTICS INC$1.2M0.04%50,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.